On July 17, 2025, Telomir Pharmaceuticals, Inc. announced that their drug Telomir-1 effectively reverses crucial gene silencing in human prostate cancer cells, outperforming traditional treatments like chemotherapy, showing significant promise in cancer therapy. The findings confirmed Telomir-1's unique ability to modulate both STAT1 and TMS1 genes, enhancing immune response without altering telomere length.